4//SEC Filing
CRANDELL KEITH 4
Accession 0000950170-24-071543
CIK 0002012593other
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 7:46 PM ET
Size
19.8 KB
Accession
0000950170-24-071543
Insider Transaction Report
Form 4
ARCH Venture Fund XII, L.P.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2024-06-10−20,000,000→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (2,336,000 underlying) - Conversion
Common Stock
2024-06-10+3,728,738→ 3,728,738 total(indirect: By ARCH Venture Fund XII, L.P.) - Conversion
Series B Preferred Stock
2024-06-10−11,924,138→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (1,392,738 underlying)
NELSEN ROBERT
10% Owner
Transactions
- Conversion
Common Stock
2024-06-10+3,728,738→ 3,728,738 total(indirect: By ARCH Venture Fund XII, L.P.) - Conversion
Series A Preferred Stock
2024-06-10−20,000,000→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (2,336,000 underlying) - Conversion
Series B Preferred Stock
2024-06-10−11,924,138→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (1,392,738 underlying)
ARCH Venture Partners XII, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2024-06-10+3,728,738→ 3,728,738 total(indirect: By ARCH Venture Fund XII, L.P.) - Conversion
Series B Preferred Stock
2024-06-10−11,924,138→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (1,392,738 underlying) - Conversion
Series A Preferred Stock
2024-06-10−20,000,000→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (2,336,000 underlying)
ARCH Venture Partners XII, LLC
10% Owner
Transactions
- Conversion
Common Stock
2024-06-10+3,728,738→ 3,728,738 total(indirect: By ARCH Venture Fund XII, L.P.) - Conversion
Series A Preferred Stock
2024-06-10−20,000,000→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (2,336,000 underlying) - Conversion
Series B Preferred Stock
2024-06-10−11,924,138→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (1,392,738 underlying)
CRANDELL KEITH
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2024-06-10−11,924,138→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (1,392,738 underlying) - Conversion
Series A Preferred Stock
2024-06-10−20,000,000→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (2,336,000 underlying) - Conversion
Common Stock
2024-06-10+3,728,738→ 3,728,738 total(indirect: By ARCH Venture Fund XII, L.P.)
GILLIS STEVEN
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2024-06-10−20,000,000→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (2,336,000 underlying) - Conversion
Common Stock
2024-06-10+3,728,738→ 3,728,738 total(indirect: By ARCH Venture Fund XII, L.P.) - Conversion
Series B Preferred Stock
2024-06-10−11,924,138→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (1,392,738 underlying)
Burow Kristina
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2024-06-10−11,924,138→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (1,392,738 underlying) - Conversion
Common Stock
2024-06-10+3,728,738→ 3,728,738 total(indirect: By ARCH Venture Fund XII, L.P.) - Conversion
Series A Preferred Stock
2024-06-10−20,000,000→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)→ Common Stock (2,336,000 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date.
- [F2]Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Documents
Issuer
Rapport Therapeutics, Inc.
CIK 0002012593
Entity typeother
Related Parties
1- filerCIK 0001219039
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 7:46 PM ET
- Size
- 19.8 KB